IIARD International Institute of Academic Research and Development

JOURNAL OF BIOLOGY AND GENETIC RESEARCH (JBGR )

E-ISSN 2545-5710
P-ISSN 2695-222X
VOL. 10 NO. 3 2024
DOI: 10.56201/jbgr.v10.no3.2024.pg17.25

---

Assessment of Qualitative breast Cancer Characteristic (Article Review)

Sarah Ali Abed

---

Abstract

Though breast cancer that has not spread is curable in 70 to 80 percent of cases diagnosed in earlier stages of the disease. Breast cancer is the most prevalent cancer diagnosed in women globally. Currently, metastatic breast cancer, indicated by distant organ metastasis, is an incurable disease. These include genetic characteristics such as sensitivities promoted by BRCA mutations, hormone receptors (oestrogen and progesterone receptors) and human epidermal growth factor receptor 2 (HER2, encoded by ERBB2) reported to be associated with breast cancer. Note: Treatment depends on molecular subtype. Breast cancer is treated in a multidisciplinary setting with systemic therapy (including chemotherapy and endocrine therapy) and locoregional (surgical and radiation therapy) procedures. These include endocrine therapy for estrogen receptor-positive tumors, anti-HER2 therapy, bone-stabilizing agents, and for BRCA mutation carriers, poly(ADP-ribose) polymerase inhibitors, chemotherapy, and, most recently, immunotherapy. Such future therapeutic concepts in breast cancer where there is the aim to escalate or de-escalate a treatment based on tumor biology, early therapy response and even treating patients according to their genomic profile. New therapeutic development is surpassed only by equitable access to the latest therapeutics regardless of socioeconomic status as the greatest challenge in breast cancer treatment of the future.

keywords:

Breast cancer, causes, risk.

---

Henry NL, Shah PD, Haider I, Freer PE, Jagsi R, Sabel MS. Chapter 88: Cancer of the
Breast. In: Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE,
eds. Abeloff’s Clinical Oncology. 6th ed. Philadelphia, Pa: Elsevier; 2020.
Jagsi R, King TA, Lehman C, Morrow M, Harris JR, Burstein HJ. Chapter 79: Malignant
Tumors of the Breast. In: DeVita VT, Lawrence TS, Lawrence TS, Rosenberg SA, eds.
DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 11th ed.
Philadelphia, Pa: Lippincott Williams & Wilkins; 2019.
National Cancer Institute. Physician Data Query (PDQ). Breast Cancer Treatment – Patient
Version. 2021. Accessed at https://www.cancer.gov/types/breast/patient/breast-treatment-
pdq on June 24, 2021.
Brinton L.A., Schairer C., Hoover R.N., Fraumeni J.F., Jr. Menstrual Factors and Risk of
Breast Cancer. Cancer Investig. 1988;6:245–254. doi: 10.3109/07357908809080645.
Collaborative Group on Hormonal Factors in Breast Cancer Menarche, menopause, and
breast cancer risk: Individual participant meta-analysis, including 118?964 women with
breast cancer from 117 epidemiological studies. Lancet Oncol. 2012;13:1141–1151. doi:
10.1016/S1470-2045(12)70425-4.
De Blok C.J.M., Wiepjes C.M., Nota N.M., van Engelen K., Adank M.A., Dreijerink
K.M.A., Barbé E., Konings I.R.H.M., den Heijer M. Breast cancer risk in transgender
people receiving hormone treatment: Nationwide cohort study in the Netherlands. BMJ.
2019;365:l1652. doi: 10.1136/bmj.l1652.
Vinogradova Y., Coupland C., Hippisley-Cox J. Use of hormone replacement therapy and
risk of breast cancer: Nested case-control studies using the QResearch and CPRD
databases. BMJ. 2020;371:m3873. doi: 10.1136/bmj.m3873.
Yue W., Wang J.P., Li Y., Fan P., Liu G., Zhang N., Conaway M., Wang H., Korach K.S.,
Bocchinfuso W., et al. Effects of estrogen on breast cancer development: Role of estrogen
receptor independent mechanisms. Int. J. Cancer. 2010;127:1748–1757. doi:
10.1002/ijc.25207. [DOI] [PMC free article] [PubMed] [Google Scholar]
Dall G.V., Britt K.L. Estrogen Effects on the Mammary Gland in Early and Late Life and
Breast Cancer Risk. Front. Oncol. 2017;7:110. doi: 10.3389/fonc.2017.00110. [DOI]
[PMC free article] [PubMed] [Google Scholar]
Singletary S.E. Rating the risk factors for breast cancer. Ann. Surg. 2003;237:474–482.
doi: 10.1097/01.SLA.0000059969.64262.87. [DOI] [PMC free article] [PubMed] [Google
Scholar]
Harlow S.D., Paramsothy P. Menstruation and the menopausal transition. Obstet. Gynecol.
Clin. N. Am. 2011;38:595–607. doi: 10.1016/j.ogc.2011.05.010. [DOI] [PMC free article]
[PubMed] [Google Scholar]
Kelsey J.L., Gammon M.D., John E.M. Reproductive factors and breast cancer. Epidemiol.
Rev. 1993;15:36–47. doi: 10.1093/oxfordjournals.epirev.a036115. [DOI] [PubMed]
[Google Scholar]
Hershman, D. L. et al. Prevention and management of chemotherapy-induced peripheral
neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical
practice guideline. J. Clin. Oncol. 32, 1941–1967 (2014).
Hanai, A. et al. Effects of cryotherapy on objective and subjective symptoms of paclitaxel-
induced neuropathy: prospective self-controlled trial. J. Natl Cancer Inst. 110, 141–148
(2018).
Kadakia, K. C., Rozell, S. A., Butala, A. A. & Loprinzi, C. L. Supportive cryotherapy: a
review from head to toe. J. Pain Symptom Manage. 47, 1100–1115 (2014).
Hou, S., Huh, B., Kim, H. K., Kim, K.-H. & Abdi, S. Treatment of chemotherapy-induced
peripheral neuropathy: systematic review and recommendations. Pain Physician 21, 571–
592 (2018).
Ahmed, R. L., Schmitz, K. H., Prizment, A. E. & Folsom, A. R. Risk factors for
lymphedema in breast cancer survivors, the Iowa Women’s Health Study. Breast Cancer
Res. Treat. 130, 981–991 (2011).
Gillespie, T. C., Sayegh, H. E., Brunelle, C. L., Daniell, K. M. & Taghian, A. G. Breast
cancer-related lymphedema: risk factors, precautionary measures, and treatments. Gland.
Surg. 7, 379–403 (2018).
Runowicz, C. D. et al. American Cancer Society/ American Society of Clinical Oncology
breast cancer survivorship care guideline. J. Clin. Oncol. 34, 611–635 (2016).
Velikova, G. et al. Quality of life after postmastectomy radiotherapy in patients with
intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised
controlled trial. Lancet Oncol. 19, 1516–1529 (2018).
Hofmann, D. et al. WSG ADAPT — adjuvant dynamic marker-adjusted personalized
therapy trial optimizing risk assessment and therapy response prediction in early breast
cancer: study protocol for a prospective, multi-center, controlled, non-blinded,
randomized, investigator initiated phase II/III trial. Trials 14, 261 (2013).
Robertson, J. F. R., Dowsett, M. & Bliss, J. M. Peri-operative aromatase inhibitor
treatment in determining or predicting long-term outcome in early breast cancer — the
POETIC Trial (CRUK/07/015) [abstract]. SABCS GS1-03 (2017).
. Kim, S.-B. et al. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line
therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised,
double-blind, placebocontrolled, phase 2 trial. Lancet Oncol. 18, 1360–1372 (2017).
Schmid, P. et al. AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line
therapy for metastatic triple-negative breast cancer (PAKT): a randomised, double-blind,
placebo-controlled, phase II trial. J. Clin. Oncol. 36 (15 Suppl.), 1007 (2018).
Jones, R. H. et al. Capivasertib (AZD5363) plus fulvestrant versus placebo plus fulvestrant
after relapse or progression on an aromatase inhibitor in metastatic ER-positive breast
cancer (FAKTION): a randomized, double-blind, placebo-controlled, phase II trial
[abstract]. J. Clin. Oncol. 37 (no. 15_suppl), 1005–1005 (2019).
Yardley, D. A. et al. Randomized phase II, doubleblind, placebo-controlled study of
exemestane with or without entinostat in postmenopausal women with locally recurrent or
metastatic estrogen receptorpositive breast cancer progressing on treatment with a
nonsteroidal aromatase inhibitor. J. Clin. Oncol. 31, 2128–2135 (2013).
Ogitani, Y. et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA
Topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with
differentiation from T-DM1. Clin. Cancer Res. 22, 5097–5108 (2016).
Tamura, K. et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-
positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion,
phase 1 study. Lancet Oncol. 20, 816–826 (2019).
Burris III, H. A., Giaccone, G. & Im, S. A. Updated findings of a first-in-human phase 1
study of margetuximab, an Fc-optimized chimeric monoclonal antibody, in patients with
HER2-positive advanced solid tumors [abstract]. Am. Soc. Clin. Oncol. Meet. 33 (no.
15_suppl), A523 (2015).
Rugo, H. S. et al. SOPHIA primary analysis: a phase 3 (P3) study of margetuximab (M) +
chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic
(met) breast cancer (MBC) after prior anti-HER2 therapies (Tx) [abstract]. J. Clin. Oncol.
37 (Suppl.), Abstr 1000 (2019).
Hyman, D. M., Piha-Paul, S. & Rodon, J. Neratinib in HER2- or HER3-mutant solid
tumors: SUMMIT, a global, multi-histology, open-label, phase 2 ‘basket’ study [abstract].
Am. Assoc. Cancer Res. Meet. CT001 (2017).
Kanemura, S., I. Tsuji, N. Ohuchi, H. Takei, T. Yokoe, Y. Koibuchi, K. Ohnuki, A. Fukao,
S. Satomi, and S. Hisamichi. 1999. "A case control study on the effectiveness of breast
cancer screening by clinical breast examination in Japan." Jpn J Cancer Res no. 90 (6):607-
doi: S0910505099801240 [pii].
Kardinah, D., B. O. Anderson, C. Duggan, I. A. Ali, and D. B. Thomas. 2013. "Short report:
Limited effectiveness of screening mammography in addition to clinical breast
examination by trained nurse midwiv

DOWNLOAD PDF

---

Back